[article] | Titre : | Strategies for European Biotechnology firms: What are the strategies that European Biotechnology firms, specially French ones, should adopt to ensure their expansion? | | Type de document : | texte imprimé | | Auteurs : | Nally Miranda, Auteur | | Année de publication : | 2013 | | Article en page(s) : | pp. 58-66 | | Langues : | Anglais (eng) |
in La Revue du Financier > 146 (2004) . - pp. 58-66| Résumé : | Biotechnology promised and still promises benefits and applications from medicine through forestry to agriculture improvement even if it faced up controversy and misunderstanding. Notwithstanding, some economic regions as Europe, and particularly France, suffers from a lack of innovation and therapeutic products in the market place compared to United States. In other words, France is still far away from the leader in terms of research development, commercialization in spite of the excellent 'brain capital' into its frontiers. According to the European Commission and also to the French Government, within 5 years, France has to catch up its delay by following a precise framework which is supported by several incentives and policies. More than that, biotech companies succeed if they scrutinize each key issue i.e. finance, human resource or marketing themselves. Obviously, the "road to success" 's construction is realizable only with the effective implication of these actors. Then, based on this deep analyze, managers and particularly business development managers have the responsibility to build an adequate strategy related to the biotech model they choose. Innovation, financing, alliances are some major and useful subjects covered by the strategy paper they write. Following this method, entrepreneurs possess a clear view of where they are willing to extend their life science business. In the 21st century, if efforts and funds are concentrated and judiciously managed by all biotech protagonists, Biotechnology will continue to be a key industry for jobs and future expansion as well as our well-being.
| | En ligne : | http://www.revuedufinancier.fr |
[article] Strategies for European Biotechnology firms: What are the strategies that European Biotechnology firms, specially French ones, should adopt to ensure their expansion? [texte imprimé] / Nally Miranda, Auteur . - 2013 . - pp. 58-66. Langues : Anglais ( eng)
in La Revue du Financier > 146 (2004) . - pp. 58-66| Résumé : | Biotechnology promised and still promises benefits and applications from medicine through forestry to agriculture improvement even if it faced up controversy and misunderstanding. Notwithstanding, some economic regions as Europe, and particularly France, suffers from a lack of innovation and therapeutic products in the market place compared to United States. In other words, France is still far away from the leader in terms of research development, commercialization in spite of the excellent 'brain capital' into its frontiers. According to the European Commission and also to the French Government, within 5 years, France has to catch up its delay by following a precise framework which is supported by several incentives and policies. More than that, biotech companies succeed if they scrutinize each key issue i.e. finance, human resource or marketing themselves. Obviously, the "road to success" 's construction is realizable only with the effective implication of these actors. Then, based on this deep analyze, managers and particularly business development managers have the responsibility to build an adequate strategy related to the biotech model they choose. Innovation, financing, alliances are some major and useful subjects covered by the strategy paper they write. Following this method, entrepreneurs possess a clear view of where they are willing to extend their life science business. In the 21st century, if efforts and funds are concentrated and judiciously managed by all biotech protagonists, Biotechnology will continue to be a key industry for jobs and future expansion as well as our well-being.
| | En ligne : | http://www.revuedufinancier.fr |
|
Accueil
Faire une suggestion Affiner la recherche Interroger des sources externesStrategies for European Biotechnology firms: What are the strategies that European Biotechnology firms, specially French ones, should adopt to ensure their expansion? / Nally Miranda in La Revue du Financier, 146 (2004)
